Royalty Report: Drugs, Drug Discovery, Genome – Collection: 286090

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Drug Discovery
  • Genome
  • Cancer
  • Disease
  • Proteins
  • cell therapy
  • Antibody
  • Pharmaceuticals
  • Cell Line
  • Biotechnology
  • Therapeutic
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286090

License Grant
Licensee of Japan and Licensor desire to conduct certain collaborative research.

Licensor grants to the Licensee of Japan a non-exclusive license under the Licensor Technology that is the subject of the Research Program solely to conduct the Research Program activities assigned to Licensee under the Research Plan.

Licensee shall have the exclusive right to utilize the Collaboration Technology to develop Collaboration Products for use and sale in the Licensee Territory and to commercialize the Collaboration Products in the Licensee Territory.

License Property
Dendritic Cell means a human dendritic cell or other antigen-presenting cell or other cells from which dendritic cells can be derived.

The developed intellectual property will aid in discovering new immunotherapy targets, and/or developing new dendritic cell-based immunotherapy products.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.

Field of Use
Field means the discovery, development, manufacture, use and sale of products that generally utilize Dendritic Cell separation, antigen engineering, and antigen or antigen gene delivery to Dendritic Cells for use in human therapies that are based on, comprise, utilize or are derived from the Licensor Technology.

IPSCIO Record ID: 288274

License Grant
Licensor of Japan and Licensee desire to conduct certain collaborative research.

The Licensor of Japan grants a non-exclusive license under any applicable Licensor know-how and Patent rights solely to conduct the Research Program activities assigned to Licensee under the Research Plan.

For the Commercial License, Licensor grants to the exclusive license in the License Territory under the Collaboration Technology to research, develop, make, have made, use, sell, offer for sale and import Collaboration Products and Licensee Products in the Licensee Territory.

Licensee shall have the exclusive right to utilize the Collaboration Technology to develop and commercialize Collaboration Products in the Licensee Territory.

License Property
Dendritic Cell means a human dendritic cell or other antigen-presenting cell or other cells from which dendritic cells can be derived.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.

The developed intellectual property will aid in discovering new immunotherapy targets, and/or developing new dendritic cell-based immunotherapy products.

Field of Use
Field means the discovery, development, manufacture, use and sale of products that generally utilize Dendritic Cell separation, antigen engineering, and antigen or antigen gene delivery to Dendritic Cells for use in human therapies that are based on, comprise, utilize or are derived from the Licensee Technology.

IPSCIO Record ID: 286091

License Grant
The Parties desire to collaborate in the joint clinical development and commercialization of Licensor Products and Collaboration Products in the European Union.

Licensee and the Japanese Licensor agree that they will jointly develop Licensor Products and Collaboration Products in the Joint Territory.

For the Commercial License, Licensor grants a sole and co-exclusive license, exclusive as to all parties except as to Licensor, with the right to grant sublicenses under the Licensor Technology and the Collaboration Technology solely to clinically develop, make, have made, use, sell, offer for sale and import Licensor Products and Collaboration Products in the Joint Territory as permitted under this Agreement.

License Property
Licensor Product means any therapeutic product developed by or on behalf of Licensor based on, derived from or incorporating the Licensee Technology that comprises Dendritic Cells that have been activated or loaded with a specific antigen, engineered antigen or antigen gene, (including without limitation a Licensor Antigen), for use in human therapy by infusion into a patient; or any service provided by or on behalf of Licensor to a patient that involves isolation or preparation of Dendritic Cells, activation or loading of a specific antigen, engineered antigen or antigen gene, (including without limitation a Licensor Antigen), and infusion of such activated or antigen loaded Dendritic Cells into a patient, wherein such service is based on, utilizes, comprises or is derived from the Licensee Technology.
Field of Use
Field means the development, manufacture, use and sale of products that generally utilize dendritic cell separation, antigen engineering, and antigen delivery to dendritic cells, for use in human therapies and that are based on, comprise, utilize or are derived from the Licensee Technology or the Collaboration Technology.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.

IPSCIO Record ID: 26799

License Grant
Licensee hereby grants to Licensor an exclusive license in the Licensor Territory, with the right to sublicense, under the Licensee Improvements and the Licensee Patents that claim such Licensee Improvements to develop, make, have made, use, import and sell Licensor Products.
License Property
This is an amended and restated collaborative license agreement between a U.S. company and a Japanese company.  The original agreement was made in 1998. The technology relates to the isolation and activation of dendritic and other antigen-presenting cells for use in human therapies.  Patents covered in the agreement are numerous and include various methods for cell separation, enrichment, and in vitor proliferation.

Trademarks licensed include Provenge and Mylovenge.

The licensor obtains commercialization rights for North America and is obligated to pay licensee a royalty on these sales–this info is included in other licensing terms. Documentation indicates one human therapy of focus is relative to prostate tumor polynucleotides.

Field of Use
Field means the discovery, development, manufacture, use and sale of products that generally utilize Dendritic Cell separation, antigen engineering, and antigen or antigen gene delivery to Dendritic Cells for use in human therapies that are based on, comprise, utilize or are derived from the Licensor Technology. The foregoing products may have applications for other human medical uses, and if Licensee demonstrates to Licensor's reasonable satisfaction that such other uses exist, then the Parties agree to negotiate in good faith an amendment to the Agreement that extends the Field to cover such additional uses, including such additional amendments as may be needed to properly cover such products for royalty purposes.

IPSCIO Record ID: 299263

License Grant
The Collaboration will seek to identify agents that modulate biological targets within the Field, including all therapeutic benefits of such agents.

Licensor grants and agrees to grant to Licensee exclusive, worldwide, except for Japan, licenses under the Licensor Patents to the extent necessary to make, have made, use and sell each compound designated as a Collaboration Lead Compound or as a Collaboration Product.

Each party hereby grants and agrees to grant to the other a non-exclusive, royalty-free license to use such partys Know-How and Patents that are conceived or reduced to practice prior to the one year anniversary of the end of the Term of the Research Collaboration.

License Property
Each Party has certain expertise in the discovery and development of agents acting in the field of cell cycle control.

The technologies relates to gene therapy and are developed in connection with performance of the Research Plan of Gene Therapy Inventions.

A Lead compound would be considered as a candidate for cGLP/cGMP studies.

Field of Use
Field shall mean research, drug discovery and development collaboration aimed at therapeutic agents to restore control of or otherwise intervene in, mis-regulated cell cycle transitions in tumor cells, vascular smooth muscle cells, or other pathological conditions.

IPSCIO Record ID: 286087

License Grant
For the Evaluation License, as to each Collaboration Cell Line provided to Licensee by Licensor, Licensor grants a non-exclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to conduct internal research evaluation of such Collaboration Cell Line.

For the Research and Development License, and effective upon Licensees acceptance of a particular Accepted Cell Line, Licensor grants a nonexclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to use each such Accepted Cell Line in the Field.

License Property
Licensor has developed and owns technology and intellectual property rights relating to methods for activating gene or protein expression in cells, referred to as the Random Activation of Gene Expression or RAGE technology, which includes the RAGE-VT technology useful for creating cell lines that express particular desired proteins.

Promptly after the Effective Date the Parties shall agree upon an initial list of specific proteins with respect to which Licensor will create RAGE libraries and promptly thereafter screen and isolate Licensor Cell Lines expressing such proteins.

Product shall mean any product containing a Candidate Compound, including any formulation, dosage form, packaged form or delivery means thereof.

RAGE Technology shall mean any and all intellectual property, whether or not patentable, that is owned or licensed by Licensor and relates to Licensors techniques for activating gene expression, which are referred to by Licensor collectively as Random Activation of Gene Expression or RAGE technology.

Field of Use
Field shall mean use of the Accepted Cell Lines by Licensee solely for Licensees internal discovery, research, development and/or commercialization of Products.  For the avoidance of doubt, the Field shall include Licensees use of the Accepted Cell Lines in connection with any bona fide collaboration between Licensee and an academic and/or corporate collaborator, provided that any compounds initially discovered or detected pursuant to such collaboration by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line shall be deemed to be Candidate Compounds.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 372646

License Grant
For the Collaboration Antigens, with respect to each Collaboration Antigen until such time as such Collaboration Antigen becomes a Discontinued Antigen or Failed Antigen, Licensor grant to Licensee of England
– an exclusive, worldwide right and license under the Licensed Licensor lP Rights, other than the XenoMouse Know-How Rights and XenoMouse Patent Rights, and the Licensor Process Know-How Rights and Licensor Process Patent Rights, and, subject to the Supplementary XenoMouse Agreement, the XenoMouse Know-How Rights and XenoMouse Patent Rights, in each case to Exploit Licensed Products that bind to and are directed against such Collaboration Antigen for use in the Commercial Field; and,
– an exclusive, worldwide right and license under the Licensor Subsequent Antigen-Specific Know-How Rights, Licensor Subsequent Antigen-Specific Patent Rights, Licensors rights in the Collaboration Know-How Rights and Collaboration Patent Rights, Licensor Oncology Know-How Rights, Licensor Oncology Patent Rights, Licensor Other Know-How Rights and Licensor Other Patent Rights, and,-
– an exclusive, worldwide right and license, under the Licensor Prior Antigen Specific Know-How Rights and Licensor Prior Antigen-Specific Patent Rights, and the other Licensed Licensor IP Rights solely to the extent necessary to enable Licensee to utilize Additional Technology applicable to such Collaboration Antigen, Collaboration Technology, Oncology Technology, Other Technology and Antigen-Specific Technology, in each case to Exploit Non-Antibody Products with respect to such Collaboration Antigen for use in the Commercial Field;
– an exclusive, worldwide right and license, under the Licensed Licensor IP Rights, other than the XenoMouse Know-How Rights, except solely to the extent necessary to enable Licensee to utilize Additional Technology applicable to such Collaboration Antigen, Antibody Technology, Collaboration Technology, Oncology Technology, Other Technology and Antigen-Specific Technology to Exploit Non-Licensed Products, other than Non-Antibody Products, XenoMouse  Patent Rights, Licensor Process Know-How Rights and Licensor Process Patent Rights, to Exploit Non-Licensed Products that bind to and are directed against such Collaboration Antigen for use in the Commercial Field.

For the Research and Development Program Licenses, with respect to each Collaboration Antigen, other than Discontinued Antigens or Failed Antigens, prior to the designation of a Candidate Drug that binds to and is directed against such Collaboration Antigen, Licensor grant to Licensee an exclusive, worldwide right and license, without the right to grant sublicenses, under and to the Licensed Licensor IP Rights applicable to such Collaboration Antigen, to conduct its obligations, and exercise its rights, under the applicable Research Program, Development Program.

For the Licensed Products, with respect to each Collaboration Antigen, other than Discontinued Antigens and Failed Antigens
— with respect to which a Candidate Drug has been selected, Licensor  grants the exclusive, worldwide, right and license, with the right to grant sublicenses through multiple tiers of sublicensees, under the Licensed Licensor IP Rights applicable to such Collaboration Antigen to Exploit Candidate Drugs that bind to and are directed against such Collaboration Antigen for use in the Commercial Field and, after Licensee has delivered an Election Notice to Licensor with respect to such Collaboration Antigen, all Licensed Products that bind to and are directed against such Collaboration Antigen for use in the Commercial Field, and,
— with respect to each Collaboration Antigen, other than Discontinued Antigens and Failed Antigens, with respect to which a Candidate Drug has been selected, Licensor grants the exclusive license and right of reference, with the right to grant sublicenses, under Licensors rights, titles and interests in and to any Registrations, to the extent not otherwise assigned, to Exploit Candidate Drugs and Licensed Products that bind to and are directed against such Collaboration Antigen for use in the Commercial Field.

For the Non-Licensed Products with respect to each Collaboration Antigen, other than Failed Antigens or Discontinued Antigens, Licensor grants
— the exclusive, worldwide, right and license, with the right to grant sublicenses, under Licensors right, title and interest in and to the Collaboration Know How Rights and Collaboration Patent Rights, Licensor Oncology Know-How Rights, Licensor Oncology Patent Rights, Licensor Other Know-How Rights, Licensor Other Patent Rights and the Licensor Subsequent Antigen-Specific Know-How Rights and Licensor Subsequent Antigen-Specific Patent Rights applicable to such Collaboration Antigen, and the other Licensed Licensor IP Rights solely to the extent necessary to enable Licensee to utilize Collaboration Technology, Oncology Technology, Other Technology and Antigen-Specific Technology, and,
— the exclusive, worldwide right and license, with the right to grant sublicenses, under the Licensor Prior Antigen-Specific Know-How Rights and Licensor Prior Antigen-Specific Patent Rights applicable to such Collaboration Antigen, in each case to Exploit Non-Antibody Products with respect to such Collaboration Antigen for use in the Commercial Field.

For the Antigen-Specific Technology, subject to any applicable Licensor In-License, with respect to each Discontinued Antigen, Failed Antigen and Non-Selected Antigen, Licensor grants
– the non-exclusive, worldwide right and license, with the right to grant sublicenses, under the Licensor Subsequent Antigen-Specific Know-How Rights and Licensor Subsequent Antigen-Specific Patent Rights applicable to each such Antigen to Exploit Non-Licensed Products, other than Non-Antibody Products, that bind to and are directed against such Antigen for use in the Commercial Field, and,
– the exclusive, worldwide right and license, with the right to grant sublicenses, under the Licensor Subsequent Antigen-Specific Know-How Rights and Licensor Subsequent Antigen-Specific Patent Rights applicable to each such Antigen to Exploit Non Antibody Products with respect to such Antigen for use in the Commercial Field.

For the Other Technology, Licensor grants a non-exclusive, worldwide right and license, with the right to grant sublicenses, under the Licensor Other Know-How Rights and Licensor Other Patent Rights for all purposes for use in the Commercial Field.

License Property
Licensor has rights in the XenoMouse® Animals, and other proprietary technology regarding the research, development, manufacture and commercialization of fully human monoclonal antibodies generated thereby.

Licensor Product shall mean a product containing an Antibody or Antibody Equivalent that binds to and is directed against a Discontinued Antigen or Failed Antigen.

Core Antibody Technology shall mean such Antibody Technology Controlled by Licensor that is Reasonably Necessary to complete the following portions of a Research Program generally in accordance with the template Research Program Work Plan, that has as its goal the delivery of Antibodies that meet the applicable Candidate Drug Target Profile criteria in accordance with industry standards
— the immunization of XenoMouse Animals,
— the generation of Antibodies from such XenoMouse Animals, and,
— the initial characterization of such Antibodies, consisting of binding such Antibodies to an antigen, epitope binning, as described in International Patent Application No. WO 03/48731, kinetic ranking, as described in International Patent Application No. WO 03/48730), affinity measurement, by BiaCore and KinExA, and sequencing; in each case as customarily practiced by Licensor, utilizing Licensor standard techniques and materials, other than transfer vectors
proprietary from Third Parties, for hybridoma or XenoMax Technology approaches.

Field of Use
The collaboration is for the development of antibody therapeutics for the treatment of oncology.
This alliance involves the joint discovery and development of therapeutic antibodies for up to 36 cancer targets to be commercialized exclusively worldwide by Licensee .

IPSCIO Record ID: 4396

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive, royalty-bearing sub-license under the Licensed Patents, including the right to grant further sublicenses solely to make, have made, use, import, sell, or have sold Licensed Products in the Territory under the Field of Use.
License Property
GRNVAC means the technology acquired by the Licensee under the Asset Contribution Agreement pertaining to the presentation of one or more antigens to the immune system using patient monocyte-derived (VAC-1) or dendritic cells or human embryonic stem cell-derived or induced pluripotent stem cell-derived antigen presenting cells (VAC-2).

018/062C
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
US
09/438,486
12-Nov-99
6,927,285
018/181C
Telomerase
US
09/843,676
26-Apr-01
7,056,513
018/210C
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
US
09/721,506
22-Nov-00
7,262,288
018/213C
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
US
10/044,692
11-Jan-02
7,560,437
018/221P
Human Telomerase Reverse Transcriptase Polypeptides
US
10/877,124
24-Nov-09
7,622,549
018/224C
Immunogenic Composition
US
11/894,643
20-Aug-07

Field of Use
Licensee has acquired Licensor’s technology directly related to the research, development and commercialization of products based on primate pluripotent embryonic stem cells.

Field of Use means use of telomerase as an antigen in an immunotherapeutic product  for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.

IPSCIO Record ID: 300871

License Grant
The Collaboration will seek to identify agents that modulate biological targets within the Field, including all therapeutic benefits of such agents.

Licensor grants an exclusive, worldwide, except for Japan, licenses under the Licensor Patents to the extent necessary to make, have made, use and sell, with the right to sublicense, each compound designated as a Licensee Lead Compound or as a Licensee Product. Such licenses with respect to an Onyx Lead Compound are co-exclusive between Licensor and Licensee.

Each party hereby grants and agrees to grant to the other a non-exclusive, royalty-free license to use such partys Know-How and Patents that are conceived or reduced to practice prior to the one year anniversary of the end of the Term of the Research Collaboration.

License Property
Each Party has certain expertise in the discovery and development of agents acting in the field of cell cycle control.

The technologies relates to gene therapy and are developed in connection with performance of the Research Plan of Gene Therapy Inventions.

A Lead compound would be considered as a candidate for cGLP/cGMP studies.

Field of Use
Field shall mean research, drug discovery and development collaboration aimed at therapeutic agents to restore control of or otherwise intervene in, mis-regulated cell cycle transitions in tumor cells, vascular smooth muscle cells, or other pathological conditions.

IPSCIO Record ID: 203320

License Grant
The parties are entering into a research collaboration to develop Telomerase vaccines in the Field.

For the Exclusive Non-DC Products License, Licensor grants an exclusive license, even as to Licensor, in the Territory under Licensor Patent Rights and Program Patent Rights, Licensor’s interest in Joint Program Patent Rights, Licensor Know-How, and Licensor’s interest in Program Know-How to make, have made, use, offer to sell, sell and/or import Non-DC Product(s) (including use for research and development of such Non-DC Product(s)) for any and all uses in the Field.

For Non-Exclusive License to Conduct Assays, Licensor grants a non-exclusive license in the Territory under Licensor Patent Rights, Licensor Know-How, Licensor Program Patent Rights, Licensor’s interest in Joint Program Patent Rights and Licensor’s interest in Program Know-How, to the extent necessary to perform assays solely to measure immunological responses to Telomerase in the research, development, and commercialization of Non-DC Products under this Agreement, including monitoring of treatment in clinical trials and in support of commercial use of such Non-DC Products.

Licensee will have the right to grant sublicenses of these rights granted.

For the Research License. Licensor grants a non-exclusive license in the Territory under the Licensor Patent Rights and Know-How, Licensor Program Patent Rights and Licensor’s interest in Joint Program Patent Rights and Licensor’s interest in Program Know-How, and Materials, solely for the purpose of conducting research in those aspects of the Research Program pertaining to DC Products and DC/Adeno/DNA Therapies.

For the Option for Commercial License to DC Products Licensor grants an exclusive option to enter into an exclusive arrangement, or non-exclusive arrangement if mutually agreed by the Parties, subject to any pre-existing obligations of Licensor to Third Parties, to develop and commercialize DC Products, DC/Non-DC Therapies and DC/Adeno/DNA Therapies, and obtain an exclusive license, or non-exclusive license if mutually agreed by the Parties, subject to any pre-existing obligations of Licensor to Third Parties, under the Licensor Patent Rights, Licensor Know-How, and Licensor’s interest in Program Patent Rights and Program Know-How, in the Field, the DC Option. Licensee’s right to exercise the DC Option shall expire two (2) years after the Effective Date, unless otherwise agreed by the Parties. Licensee shall be entitled to exercise the DC Option by providing written notice to Licensor at any time prior to expiration of the DC Option.

License Property
Licensors rights relate to Telomerase and dendritic cell-based vaccines, and is involved in on-going human clinical trials utilizing Telomerase as an antigen in dendritic cell-based vaccines.

Telomerase, also called terminal transferase, is a ribonucleoprotein that adds a species-dependent telomere repeat sequence to the 3' end of telomeres.

DC Product shall mean a Product that comprises a Dendritic Cell.  A Dendritic Cell or DC shall mean a mammalian cell that, as part of an ex vivo or in vitro preparation, can be used to present an antigen to the immune system. For the avoidance of doubt, Dendritic Cells shall include, but not be limited to, the type of cells commonly referred to scientifically as dendritic cells.

Non-DC Product shall mean any Product that is not a DC Product, DC/Non-DC Therapy or a DC/Adeno/DNA Therapy, regardless of whether such Product employs any delivery enhancement technology (e.g. with or without electroporation). Non-DC Products shall include, but not be limited to, Adeno/DNA Products.

Field of Use
The Field shall mean the treatment, modulation and/or prophylaxis of cancer, and/or other diseases mediated by hyperproliferation of cells, in humans.

Licensee has expertise and access to intellectual property rights related to various vaccine platform technologies, including adenovirus and DNA-based vaccines.

Collaboration and license agreement is to develop a cancer vaccine targeting telomerase utilizing Licensor's expertise in vaccine technologies.

IPSCIO Record ID: 230777

License Grant
Licensor hereby grants to Licensee the exclusive license right to use the Subject Technology, including, without limitation, the right to make, have made, use, offer for sale, sell, and import any and all products, methods and services utilizing the Subject Technology and/or the Intellectual Property applicable to the Subject Technology.
License Property
The patents are for Chimeric antibodies comprising antigen binding sites and B and T cell epitopes, and,  Immunization of infants.

The right is for a proprietary immunotherapy platform technology.

Field of Use
The agreement is for all possible fields of use.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.